๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies

โœ Scribed by R. O. Dillman

Publisher
Springer
Year
2006
Tongue
English
Weight
104 KB
Volume
6
Category
Article
ISSN
0372-8722

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

The advantage of residualizing radiolabe
The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody
โœ M. Jules Mattes; Lisa B. Shih; Serengulam V. Govindan; Robert M. Sharkey; Gaik L ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 104 KB

CD22 antibodies (Abs) bound to B-cell lymphomas are known to be internalized and catabolized rapidly. Therefore, it would be expected that use of CD22 as a target for radioimmunotherapy should be enhanced by the use of "residualizing" radiolabels, which are trapped within the cell after catabolism o

Treatment of B-cell non-Hodgkin's lympho
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
โœ Stefano Sacchi; Massimo Federico; Giuseppe Dastoli; Claudia Fiorani; Giovanni Vi ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 232 KB

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have